 | ||
Headquarters New South Wales, Australia | ||
Biotron limited anti viral drug company on sky business
Biotron Limited (Biotron) is an Australian biotechnology company based in Sydney, NSW. Biotron develops novel small molecule antiviral therapeutics targeting Hepatitis C and HIV. Biotron has identified a new class of viral proteins as targets for potential intervention, and is developing novel small molecule therapeutics that target these proteins, specifically the p7 protein of Hepatitis C and Vpu protein of HIV. Biotron’s lead drug, BIT225, is in clinical development for treatment of both HIV and Hepatitis C, as well as the hard to treat HIV/Hepatitis C co-infected population. It offers potential as a new class of oral direct-acting antiviral drug for Hepatitis C that may be used in combination with either current treatment strategies or with new classes of direct-acting antiviral drugs in development.